FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	$\Gamma$	20E 40
vvasiiiigtoii,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Berg Aaron  (Last) (First) (Middle)  C/O AMARIN PHARMA, INC.  440 US HIGHWAY 22  (Street)					2. Issuer Name and Ticker or Trading Symbol AMARIN CORP PLC\UK [ AMRN ]  3. Date of Earliest Transaction (Month/Day/Year) 08/02/2021  4. If Amendment, Date of Original Filed (Month/Day/Year)								(Che	S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director					
BRIDGEWATER NJ 08807												X Form filed by One Reporting Person  Form filed by More than One Reporting  Person							
(City)	(St	ate)	(Zip)																
		Tab	le I - Non-			_			<del>-</del>	Disp					-				
1. Title of Security (Instr. 3)  2. Transic Date (Month/I				Date	action 2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Of Code (Instr. 5)		ties Acquired (A) I Of (D) (Instr. 3,		4 and Securit Benefic		s illy ollowing	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A) (D)	) or ) Price		Transact	Transaction(s) (Instr. 3 and 4)			(111341.4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/		ransaction code (Instr.				6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				c	ode \	,	(A)	(D)	Date Exercisab		expiration Date	Title	or Nu of	ount mber ares					
Stock Option (Right to Buy)	\$4.22	08/02/2021			A		96,750		(1)	0	8/02/2031	Ordinar Shares <sup>(2)</sup>		,750	\$0.00	96,750	)	D	
Restricted Stock Units <sup>(3)</sup>	\$0.00	08/02/2021			A		71,650		(4)		(5)	Ordinar Shares <sup>(2)</sup>		,650	\$0.00	71,650	)	D	

## **Explanation of Responses:**

- 1. On August 2, 2021, the Reporting Person was granted an option to purchase 96,750 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "2020 Plan"). The shares subject to this option shall vest and become exercisable over four years, with 25% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 12 calendar quarters on the last day of each
- 2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 3. Each restricted stock unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.
- 4. On August 2, 2021, the Reporting Person was granted 71,650 RSUs under the 2020 Plan. These RSUs vest in three equal installments on each of July 31, 2022, July 31, 2023 and July 31, 2024.
- 5. Not applicable

## Remarks:

The equity grants referenced above were supported by recommendations of the Company's independent compensation consultant and approved by the Remuneration Committee of the Company's Board of Directors. In the case of a Change of Control (as defined in the Issuer's stock incentive plan), the grants described in this Form 4 vest in full. As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 1,491,043 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and RSUs outstanding under the Issuer's stock incentive plans, including but not limited to certain performance-based RSUs that are earned only if certain pre-defined operational milestones are achieved and, in certain cases, then vest only if the recipient remains with the company for an extended period of time.

/s/ Michael W. Kalb, by power

08/04/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.